University of Surrey

Test tubes in the lab Research in the ATI Dance Research

Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer

Cunningham, D, Falk, S and Jackson, DL (2002) Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer British Journal of Cancer, 86 (11). pp. 1677-1683.

Full text not available from this repository.

Abstract

The combination of irinotecan plus 5-fluorouracil and folinic acid has clinical and survival benefits over 5-fluorouracil and folinic acid alone in the setting of first line treatment of metastatic colorectal cancer. The aim of this cost-effectiveness analysis was to compare the economic implications, from a UK health commissioner perspective, of the two treatment arms (de Gramont regimen) in this setting. Resource utilisation data collected prospectively during the study were used as a basis for estimating cumulative drug dosage, chemotherapy admistration, and treatment of complications during first line therapy. Resource utilisation associated with further chemotherapy in patients who had progressed during the study was derived from a retrospective case note review. Drug acquisition costs were derived from the British National Formulary (September, 2001) and unit costs for clinical consultation and services were taken from the latest relevant cost database. Cumulative costs per patient associated with further chemotherapy were lower in the irinotecan plus 5-fluorouracil and folinic acid treatment arm. Based on incremental costs per life-year gained of £14794, the combination of irinotecan plus 5-fluorouracil and folinic acid can be considered cost-effective by commonly accepted criteria compared with 5-fluorouracil and folinic acid alone. Thus, clinical and economic data demonstrate that irinotecan, either in combination with irinotecan plus 5-fluorouracil and folinic acid in the first line setting or as monotherapy in the second line setting, has a major role in the management of metastatic colorectal cancer.

Item Type: Article
Subjects : Economics
Authors :
NameEmailORCID
Cunningham, DUNSPECIFIEDUNSPECIFIED
Falk, SUNSPECIFIEDUNSPECIFIED
Jackson, DLd.jackson@surrey.ac.ukUNSPECIFIED
Date : 7 June 2002
Identification Number : https://doi.org/10.1038/sj.bjc.6600204
Uncontrolled Keywords : irinotecan; metastatic colorectal cancer; cost effectiveness analysis; 5-fluorouracil; chemotherapy; first line therapy
Depositing User : Symplectic Elements
Date Deposited : 16 May 2017 15:38
Last Modified : 18 May 2017 13:13
URI: http://epubs.surrey.ac.uk/id/eprint/820956

Actions (login required)

View Item View Item

Downloads

Downloads per month over past year


Information about this web site

© The University of Surrey, Guildford, Surrey, GU2 7XH, United Kingdom.
+44 (0)1483 300800